Your category's advertising benchmark is noise. The cross-industry median is not.
We read every US public filer that disclosed advertising expense for calendar 2024 — 1,633 of them — and computed how much the number varies inside an industry against how much it varies between industries. The spread inside a category is far larger than the gap between categories, which means the peer benchmark on your slide does not predict your company. Every row, every rejection and every prior is published.
The typical company spends about 2% to 3.3% of revenue on advertising, and that is true whatever industry it is in.
Enterprise software, drug development and a miscellaneous business-services bucket returned medians of 2.01%, 3.22% and 3.30%. Three industries with almost nothing in common, landing within 1.3 percentage points of each other.
The registered question, written before any retrieval
Within a given industry category, does disclosed advertising intensity — advertising expense divided by revenue — cluster tightly enough that a peer band means anything?
| # | Candidate | Measured as | Prior | Outcome |
|---|---|---|---|---|
| C1 | Intensity clusters tightly. Category is the dominant variable. | CV < 0.5 | 25% | Dead. Every category above 1.0 |
| C2 | Intensity spreads widely. Category tells you almost nothing. | CV ≥ 1.0 | 40% | This is the result |
| C3 | A band exists but is broad. | 0.5 ≤ CV < 1.0 | 25% | No |
| C4 | Too few filers tag both concepts. | n < 15 per category | 10% | No. 238 rows survived validation |
C2 was the outcome I least wanted, and it was registered at the top of its band anyway, because it kills the saleable version of this work — the per-category benchmark chart — and replaces it with something harder to sell and more defensible.
The measurement
| SIC | Category | n | Median | Mean | Std dev | CV |
|---|---|---|---|---|---|---|
| 7372 | Services — Prepackaged Software | 137 | 2.01% | 4.13% | 9.13% | 2.21 |
| 2834 | Pharmaceutical Preparations | 61 | 3.22% | 28.22% | 172.17% | 6.10 |
| 7389 | Services — Business Services, NEC | 40 | 3.30% | 7.64% | 11.55% | 1.51 |
A coefficient of variation above 1.0 means the standard deviation exceeds the mean. All three categories are above it. The median within-category CV is 2.21, against a registered threshold of 0.5 for the tight-cluster candidate.
Join rate: 1,404 of 1,633 filers, or 86.0%. The 229 that tagged advertising but no matching revenue concept are counted here rather than dropped silently.
Positive control, run before anything else. Procter & Gamble present at $9.6bn advertising on $84.0bn revenue. If a known large advertiser had not survived the join and the validation, every zero in the pass would have been meaningless.
The number that is worth more than the verdict
Three industries with nothing in common, and the typical company in each spends between 2% and 3.3% of revenue on advertising. Meanwhile the spread inside each category is enormous.
So the category is simultaneously useless and unnecessary: useless because it does not predict any individual company, unnecessary because the typical value is roughly the same everywhere.
The question a marketing leader should be asking is not what their category spends. The answer is about 2 to 3%, like everyone else. It is what does my business model spend, and have I chosen it deliberately.
What that looks like on named companies
| Company | Period | Intensity | Multiple |
|---|---|---|---|
| Take-Two Interactive | FY to Mar 2025 | 22.26% | ~7x |
| Take-Two Interactive | FY to Mar 2026 | 19.34% | ~6x |
| Maplebear (Instacart) | CY2024 | 13.53% | ~4x |
| DoorDash | CY2024 | 12.12% | ~4x |
| Electronic Arts | FY to Mar 2026 | 4.70% | ~1.5x |
| Uber | CY2024 | 4.32% | ~1.5x |
| Lyft | CY2024 | 2.55% | ~1x |
None of this is a category effect. DoorDash and Instacart sit at four times typical because paid customer acquisition is their business model. Uber, which runs the same deliveries alongside a rides business that does not buy its customers, sits near the median. Take-Two's step change came in the fiscal year the Zynga acquisition closed.
The Zynga explanation is a hypothesis. Advertising stepped 4.08 times in the fiscal year to March 2023 — from $297.3m to $1,212.5m — and the acquisition closed in May 2022, inside that year. The timing and the mechanism fit. The filing has not been read, and that stays marked wherever this appears.
The sensitivity test, run because one number demanded it
Pharma's CV of 6.10 with a 172% standard deviation is not a finding, it is a question. One filer answered it.
ONE WORLD PRODUCTS, INC. — advertising intensity 1,349% on revenue of $4,863.
Not $4.8 million. Four thousand, eight hundred and sixty-three dollars. The ratio is arithmetically correct and conceptually meaningless.
| SIC | n after | Median | CV before | CV after |
|---|---|---|---|---|
| 7372 | 137 | 2.01% | 2.21 | 2.21 |
| 2834 | 60 | 3.22% | 6.10 | 1.49 |
| 7389 | 40 | 3.30% | 1.51 | 1.51 |
Median CV after the cut: 1.51. Still the wide-spread verdict. The result does not depend on how the outliers are treated, which is the only reason it is safe to state. The pharma CV does — it moved by a factor of four on one company — and anyone quoting 6.10 without that sentence is quoting an artifact.
The 100% cut is crude and we are saying so rather than dressing it up. Zapata Quantum sits at 97.6% on $3.9m of revenue and survives the cut with the same problem as the company that did not. A revenue floor would be the better instrument. It was not in the registered design, so it is not applied here.
What we threw away, and why
Every row entering the three categories was checked against the filer's own concept history. 12 of 250 were rejected — 11 for material conflicts, one for a name mismatch. All twelve are published because a validation step nobody can see is a claim rather than a check.
| Filer | What the conflict was | Why it matters |
|---|---|---|
| Universe Pharmaceuticals | same period tagged 5,144,579 and 5,144,579,000 | Order of magnitude. Sat fifth in the raw ranking. |
| Eli Lilly | 1,400,000,000 against 1,440,000,000, 2.9% apart | Above the 1% threshold and it cost a major filer. The threshold is a tuning question, stated rather than silently changed. |
| Backblaze | 3.0m against 4.2m | A genuine disagreement, not rounding. |
| Standard Biotools | 2.6m against 5.9m | A genuine disagreement, not rounding. |
| eGain | 180k against 2.1m | A genuine disagreement, not rounding. |
| Reshape Lifesciences | frame says RESHAPE LIFESCIENCES, concept says VYOME HOLDINGS | A legitimate rename, rejected by the name check. The one false positive of the twelve. |
Eli Lilly is the uncomfortable one. 1,400,000,000 against 1,440,000,000 — 2.9% apart, above the 1% threshold, and it cost a major filer. At 1% it rejects Lilly; at 5% it keeps Lilly and still catches every order-of-magnitude error. The registered design did not specify a number, so the one used is ours and should be set deliberately before the next pass.
What this study cannot tell you
- Disclosure of this concept is voluntary. 1,633 filers is a lot and it is not a census. Companies that disclose advertising may differ systematically from those that do not, and this design cannot remove that selection effect.
- One year. CY2024 only, plus named companies read at their own fiscal year ends. No trend claim.
- SIC is a crude grouping. It is what the data carries. A category that holds a direct-to-consumer brand buying every customer and a wholesaler buying none is not a peer group, and that may be most of what the wide spread is measuring.
- Nothing here reads a filing's prose. www.sec.gov is unreachable from the workspace that ran this, so every figure is a tagged fact and the Zynga explanation stays a hypothesis.
- Advertising expense is an input. No row measures what it bought.
How this page changes
A standing study, not an article. Corrections are published in place and dated, never applied quietly.
| Measurement | Cadence |
|---|---|
| Category CVs and medians | When CY2025 frames populate |
| Named-company intensities | On each company's 10-K |
| Validation rejections | Every re-run, republished in full |
| Date | What changed |
|---|---|
| 2026-10-25 | Published from the pass of 2026-10-24. Two treatment choices are ours rather than registered — the 100% cut and the 1% materiality threshold — and both say so on the page. |
This study re-runs when the next year of filings lands.
Sound Decisions carries each re-run and each correction, with the registered question written before the data is pulled.
Subscribe to Sound Decisions